- Educatie
- Bron: Campus Sanofi
- 1 okt 2026
Breathing New Life into COPD
Rethinking COPD, One Question at a Time
In this expert series, Professor Klaus Rabe shares his clinical perspective on some of the biggest challenges in COPD today – from identifying the right biomarkers, to understanding the role of eosinophils, to addressing the emotional and physical burden patients carry every day.
Professor Rabe is also joined by Professor Brian Lipworth for a cross-disease conversation on whether eosinophils behave the same way in COPD as they do in asthma. Together, these discussions offer a grounded, clinically relevant look at where COPD care is heading – and what clinicians need to know to keep up.
Interview with Professor Brian Lipworth
What does it really take to move the needle in severe asthma care?
A collection of short, informative videos exploring FeNO as a:
- predictive biomarker,
- the clinical relevance of mucus plugging on CT,
- why type 2 comorbidities extend far beyond the lungs, and
- why small airways disease deserves far more attention than it typically gets.
COPD Interviews with Prof. Klaus Rabe
Prof. Klaus Rabe
The Future of Biologics in COPD
Are we treating COPD too late?
In this interview, Professor Rabe discusses how a deeper understanding of disease endotypes and biomarkers could expand the role of biologics, enabling earlier and more targeted intervention in the future.
Prof. Klaus Rabe
COPD: A Disease in Its Own Right
"… it's time to stop borrowing from asthma."
In this engaging interview, professor Rabe explains why COPD is a distinct disease with its own biology and discusses how advances in immunology and cross-specialty collaboration are opening new possibilities for innovation in COPD care.
Prof. Klaus Rabe
The Bigger Picture in COPD
"Biomarkers matter, but don't forget the patient in front of you."
Professor Rabe brings us back to basics with a powerful reminder: eosinophils are just one piece of a much larger clinical puzzle.
Prof. Klaus Rabe
Recognizing Inflammation in COPD
"For the first time, we have a different answer."
For many years, blood eosinophils were rarely considered in COPD because they had little impact on clinical decision making. Professor Rabe reflects on how they may today open new opportunities for more targeted treatment approaches.
Prof. Klaus Rabe
Depression and Anxiety in COPD
Depression and anxiety are common but frequently under recognized in COPD. Klaus Rabe discusses why clinicians should actively explore the emotional and social impact of the disease and address mental health as part of routine patient care.
COPD and Asthma: Are Eosinophils Different?
Prof. Klaus Rabe and prof. Brian Lipworth
COPD and Asthma: Are Eosinophils Different?
Blood eosinophils are a hot topic in both asthma and COPD. In this candid exchange, Professor Rabe and Professor Lipworth debate whether blood eosinophils are a true disease driver or simply a biomarker, why the 300 cells/µL threshold matters, and what clinical trial data is telling us.
Professor Rabe is a leading international expert in asthma and COPD. He serves as Scientific Director of the LungenClinic Grosshansdorf and is affiliated with the Christian Albrechts University of Kiel, Germany.
Professor Rabe is widely recognized for his contributions to respiratory research, particularly in the areas of airway inflammation, asthma–COPD overlap, disease phenotyping, and the translation of scientific evidence into clinical practice. He has authored numerous high impact publications and has played a key role in the development of international treatment guidelines. Professor Rabe is a frequent invited speaker at major global respiratory congresses.
Professor Lipworth is a distinguished respiratory physician and researcher, and Professor of Allergy and Respiratory Medicine at the University of Dundee, affiliated with Ninewells Hospital and Medical School, Scotland, UK.
Professor Lipworth is internationally recognized for his extensive research in asthma and COPD, with particular expertise in airway pharmacology, small airways disease, type 2 inflammation, and inhaled therapies.
Professor Lipworth has authored more than 400 peer reviewed publications and is a frequent invited speaker at major international respiratory congresses. His work has had a significant impact on the clinical management of asthma and COPD, helping to translate mechanistic insights into everyday practice.
Expert explaining key treatable traits in COPD: eosinophilic inflammation
Watch Prof. Brian Lipworth share insights on eosinophilic inflammation (5 minutes)
Webcast: Targeting COPD with type 2 inflammation - emerging biologic landscape
Explore the Latest Insights in COPD Management and Biologic Therapies.
Expertvideo: Complexe type 2-inflammatie, verfrissend eenvoudig
Professor Lipworth geeft snel inzicht met het bucket-model.
Expert explaining key treatable traits in COPD: eosinophilic inflammation
Watch Prof. Brian Lipworth share insights on eosinophilic inflammation (5 minutes)
Webcast: Targeting COPD with type 2 inflammation - emerging biologic landscape
Explore the Latest Insights in COPD Management and Biologic Therapies.
Expertvideo: Complexe type 2-inflammatie, verfrissend eenvoudig
Professor Lipworth geeft snel inzicht met het bucket-model.
Neem contact op
MAT-BE-2600936 v.1.0 08/2026